Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ antagonists & inhibitors
Biomarkers, Tumor
/ metabolism
Disease Progression
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
Middle Aged
Neoplasms
/ drug therapy
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
Survival Rate
Young Adult
Immune checkpoint inhibitor
pseudoprogression
response evaluation criteria in solid tumors
treatment beyond progression
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
06
09
2019
revised:
14
11
2019
accepted:
05
12
2019
pubmed:
20
2
2020
medline:
15
5
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
PD(L)1 antibodies (anti-PD(L)-1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti-PD(L)-1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti-PD(L)-1. All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti-PD(L)-1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. A total of 169 patients treated with anti-PD(L)-1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non-small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT-scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune-related response evaluations may require further attention.
Sections du résumé
BACKGROUND
PD(L)1 antibodies (anti-PD(L)-1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti-PD(L)-1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti-PD(L)-1.
METHODS
All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti-PD(L)-1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD.
RESULTS
A total of 169 patients treated with anti-PD(L)-1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non-small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT-scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07).
CONCLUSIONS
A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune-related response evaluations may require further attention.
Identifiants
pubmed: 32074405
doi: 10.1002/cam4.2797
pmc: PMC7163099
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2643-2652Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Ann Oncol. 2016 Jun;27(6):1178-9
pubmed: 27091806
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Ann Oncol. 2017 Aug 1;28(8):1996-2001
pubmed: 28459943
JAMA Oncol. 2017 Nov 1;3(11):1511-1519
pubmed: 28662232
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
JAMA Oncol. 2016 Sep 1;2(9):1179-86
pubmed: 27243803
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
JAMA Oncol. 2017 Nov 1;3(11):1473-1474
pubmed: 28662228
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oncotarget. 2017 Jun 3;8(34):57889-57897
pubmed: 28915720
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Eur Urol. 2017 Sep;72(3):368-376
pubmed: 28410865
Ann Oncol. 2019 Mar 1;30(3):385-396
pubmed: 30657859
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
JAMA Oncol. 2018 May 1;4(5):717-721
pubmed: 29423503
Cancer Med. 2020 Apr;9(8):2643-2652
pubmed: 32074405
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Semin Oncol. 2017 Feb;44(1):3-7
pubmed: 28395760